JP7772501B2 - サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体 - Google Patents

サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体

Info

Publication number
JP7772501B2
JP7772501B2 JP2020555100A JP2020555100A JP7772501B2 JP 7772501 B2 JP7772501 B2 JP 7772501B2 JP 2020555100 A JP2020555100 A JP 2020555100A JP 2020555100 A JP2020555100 A JP 2020555100A JP 7772501 B2 JP7772501 B2 JP 7772501B2
Authority
JP
Japan
Prior art keywords
cancer
disease
alkyl
infection
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521120A5 (https=
JP2021521120A (ja
Inventor
キヤン ナム，
ジェスン キム，
イジン ジョン，
ドンフン ユ，
ムヨン ソ，
ドンシク パク，
ヤン アイクホフ，
グンター ツィシンスキー，
Original Assignee
キュリエント カンパニー， リミテッド
リード ディスカバリー センター ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュリエント カンパニー， リミテッド, リード ディスカバリー センター ゲーエムベーハー filed Critical キュリエント カンパニー， リミテッド
Publication of JP2021521120A publication Critical patent/JP2021521120A/ja
Publication of JP2021521120A5 publication Critical patent/JP2021521120A5/ja
Priority to JP2023131904A priority Critical patent/JP2023138858A/ja
Application granted granted Critical
Publication of JP7772501B2 publication Critical patent/JP7772501B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020555100A 2018-04-11 2019-04-11 サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体 Active JP7772501B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023131904A JP2023138858A (ja) 2018-04-11 2023-08-14 サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656070P 2018-04-11 2018-04-11
US62/656,070 2018-04-11
PCT/EP2019/059302 WO2019197549A1 (en) 2018-04-11 2019-04-11 Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023131904A Division JP2023138858A (ja) 2018-04-11 2023-08-14 サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2021521120A JP2021521120A (ja) 2021-08-26
JP2021521120A5 JP2021521120A5 (https=) 2021-11-11
JP7772501B2 true JP7772501B2 (ja) 2025-11-18

Family

ID=66334385

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555100A Active JP7772501B2 (ja) 2018-04-11 2019-04-11 サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体
JP2023131904A Pending JP2023138858A (ja) 2018-04-11 2023-08-14 サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023131904A Pending JP2023138858A (ja) 2018-04-11 2023-08-14 サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体

Country Status (14)

Country Link
US (1) US11945822B2 (https=)
EP (1) EP3774810A1 (https=)
JP (2) JP7772501B2 (https=)
KR (1) KR20200141487A (https=)
CN (1) CN112313235A (https=)
AU (1) AU2019250507B2 (https=)
BR (1) BR112020020768A2 (https=)
CA (1) CA3095880A1 (https=)
IL (1) IL277770B2 (https=)
MX (1) MX2020010675A (https=)
MY (1) MY199647A (https=)
PH (1) PH12020551639A1 (https=)
SG (1) SG11202009724YA (https=)
WO (1) WO2019197549A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020186196A1 (en) * 2019-03-13 2020-09-17 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
EP3725788A1 (en) * 2019-04-15 2020-10-21 Bayer AG Novel heteroaryl-substituted aminoalkyl azole compounds as pesticides
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
CA3161869A1 (en) 2019-12-20 2021-06-24 Yonghan Hu Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof
WO2021176045A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
CN112079781B (zh) * 2020-09-30 2022-11-22 苏州康润医药有限公司 5-溴-1-甲基-1h-吡唑-3-胺的合成方法
US20250263413A1 (en) * 2020-12-02 2025-08-21 Qurient Co., Ltd. Compounds having cyclin-dependent kinase(cdk)-inhibitory function
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
CN114195710A (zh) * 2021-12-20 2022-03-18 上海彩迩文生化科技有限公司 一种喹啉类胺甲基化合物的制备方法
KR20240112230A (ko) * 2023-01-11 2024-07-18 주식회사 티움바이오 사이클린 의존성 키나아제 9 저해제로서의 피라졸로피리미딘 유도체
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
KR102912267B1 (ko) * 2023-04-20 2026-01-15 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
WO2025024726A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinase
CN117756747A (zh) * 2023-12-21 2024-03-26 济宁医学院 一种n-苯基含氮多元环季铵盐类化合物的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511952A (ja) 2012-03-01 2015-04-23 リード ディスカバリー センター ゲーエムベーハー 選択的サイクリン依存性キナーゼ阻害剤としてのピラゾロ−トリアジン誘導体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) * 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
CN1880317B (zh) * 2002-09-04 2012-10-10 先灵公司 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
AR047969A1 (es) * 2004-02-25 2006-03-15 Schering Corp Pirazolotriazinas como inhibidores de quinasa
JP2009007342A (ja) * 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
EP2634189A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3129371B1 (en) * 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
ES2899196T3 (es) * 2015-03-09 2022-03-10 Aurigene Discovery Tech Ltd Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK
WO2019144149A2 (en) * 2018-01-22 2019-07-25 Fred Hutchinson Cancer Research Center Treatment methods for pancreatic tumors associated with the worst prognosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511952A (ja) 2012-03-01 2015-04-23 リード ディスカバリー センター ゲーエムベーハー 選択的サイクリン依存性キナーゼ阻害剤としてのピラゾロ−トリアジン誘導体

Also Published As

Publication number Publication date
BR112020020768A2 (pt) 2021-01-19
MX2020010675A (es) 2020-10-28
IL277770A (en) 2020-11-30
KR20200141487A (ko) 2020-12-18
CA3095880A1 (en) 2019-10-17
JP2023138858A (ja) 2023-10-02
MY199647A (en) 2023-11-14
IL277770B2 (en) 2024-01-01
EP3774810A1 (en) 2021-02-17
JP2021521120A (ja) 2021-08-26
NZ768649A (en) 2024-10-25
AU2019250507B2 (en) 2023-09-28
WO2019197549A1 (en) 2019-10-17
SG11202009724YA (en) 2020-10-29
PH12020551639A1 (en) 2021-07-05
CN112313235A (zh) 2021-02-02
IL277770B1 (en) 2023-09-01
US11945822B2 (en) 2024-04-02
US20210147427A1 (en) 2021-05-20
AU2019250507A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
JP7772501B2 (ja) サイクリン依存性キナーゼの選択的インヒビターとしてのピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体
JP7406501B2 (ja) 薬学的に活性なピラゾロ－トリアジン誘導体および／またはピラゾロ－ピリミジン誘導体
CN101827848B (zh) 作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物
JP2025019114A (ja) Ｊａｋ１阻害剤としてのピペリジン－４－イルアゼチジン誘導体
CN103930416B (zh) 作为激酶抑制剂的苄腈衍生物
AU2015261812B2 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
EA035499B1 (ru) Новые ингибиторы глутаминазы
JP7307729B2 (ja) メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
CZ304344B6 (cs) Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
JP7597709B2 (ja) 置換インドールおよびインダゾール化合物
BRPI0616701A2 (pt) 2-amino-7,8-diidro-6h-pirido [4,3-d] pirimidin-5-onas
AU2009267161A1 (en) Naphthyridininones as Aurora kinase inhibitors
KR20180061316A (ko) 암의 치료 및 후성유전학을 위한 화합물
ES2308260T3 (es) Derivados de imidazopiridinas como inhibidores de no-sintasa inducible.
KR20250012101A (ko) Parg의 억제제
US12606561B2 (en) Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors
KR20210038909A (ko) 히스타민 h4-수용체 저해제로서 피리도피리미딘류
US20240343732A1 (en) Compounds for degradation of cyclin-dependent kinase 7(cdk7)
RU2809779C2 (ru) Производные пиразолотриазина и/или пиразолопиримидина в качестве селективного ингибитора циклинзависимой киназы
JP2008532980A (ja) アミド置換された６−フェニルフェナントリジン
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
WO2015016195A1 (ja) Ｗｎｔシグナル阻害剤
大橋知洋 Discovery of Novel Hedgehog Signaling Inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210930

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230501

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230922

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251106

R150 Certificate of patent or registration of utility model

Ref document number: 7772501

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150